EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,901 JPY | +1.32% |
|
-2.32% | -16.32% |
| Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
| Apr. 01 | BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug | MT |
| Sales 2024 * | 735B 4.75B | Sales 2025 * | 778B 5.03B | Capitalization | 1,692B 10.94B |
|---|---|---|---|---|---|
| Net income 2024 * | 41.04B 265M | Net income 2025 * | 49.99B 323M | EV / Sales 2024 * | 2.07 x |
| Net cash position 2024 * | 172B 1.11B | Net cash position 2025 * | 184B 1.19B | EV / Sales 2025 * | 1.94 x |
| P/E ratio 2024 * |
41.4
x | P/E ratio 2025 * |
34
x | Employees | 11,076 |
| Yield 2024 * |
2.75% | Yield 2025 * |
2.81% | Free-Float | 93.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
| 1 day | +1.32% | ||
| 1 week | -2.32% | ||
| Current month | -5.07% | ||
| 1 month | -6.78% | ||
| 3 months | -15.90% | ||
| 6 months | -27.63% | ||
| Current year | -16.32% |
1 week
5 795.00
6 052.00
1 month
5 795.006 441.00
Current year
5 795.007 818.00
1 year
5 795.0011 250.00
3 years
5 011.0012 765.00
5 years
5 011.0012 765.00
10 years
3 878.0012 765.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Fumihiko Ike
BRD | Director/Board Member | 71 | 21-05-31 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.78% | 15 M€ | +4.29% | ||
| 1.23% | 251 M€ | +13.08% | ||
| 1.13% | 31,732 M€ | +11.76% | - | |
| 1.12% | 1,198 M€ | +11.02% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 5,901 | +1.32% | 1,410,700 |
| 24-04-18 | 5,824 | -1.36% | 1,118,500 |
| 24-04-17 | 5,904 | -2.45% | 1,041,800 |
| 24-04-16 | 6,052 | +0.67% | 797,900 |
| 24-04-15 | 6,012 | -0.48% | 648,000 |
Delayed Quote Japan Exchange, April 19, 2024 at 02:34 am EDT
More quotes
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
5,901
JPY
Average target price
8,193
JPY
Spread / Average Target
+38.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.32% | 10.95B | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
- Stock Market
- Equities
- 4523 Stock
